On May 30, 2018 ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, reported that Chief Executive Officer, Gil Beyen, will present at the Jefferies Global Healthcare Conference on Wednesday, June 6, 2018 at The Grand Hyatt, in New York City (Press release, ERYtech Pharma, MAY 30, 2018, View Source [SID1234526951]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:

Conference: Jefferies Global Healthcare Conference
Date: June 6, 2018
Presentation Time: 11:00 AM EDT / 5:00 CET
A live webcast of the presentation will be available online from the investor relations page of the company’s corporate website at View Source and via the below link: View Source

Following, the live webcast, an archive of the presentation will be available on the company website for 30 days, under the "Investors" section at investors.erytech.com

On May 30, 2018 Navidea Biopharmaceuticals (NYSE MKT: NAVB) ("Navidea" or "the Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, reported it will present at the 8th Annual LD Micro Invitational Conference in Bel-Air, CA being held June 4-6, 2018 (Press release, Navidea Biopharmaceuticals, MAY 30, 2018, View Source [SID1234526950]). Jed Latkin, Chief Financial and Operating Officer of Navidea, will be giving a corporate presentation focused on Navidea’s clinical programs. In additional, Michael Goldberg, M.D., Chief Executive Officer of Navidea, along with other members of management will attend the 2018 BIO International Convention in Boston, MA being held June 4-7, 2018 to participate in meetings with potential clinical and commercial partners, investors, and other parties.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: 8th Annual LD Micro Invitational
Presentation Date: Monday, June 4, 2018
Presentation Time: 1:00pm PT
Location: Luxe Sunset, Bel-Air, CA

The presentation at the LD Micro Invitational Conference will be webcast live and remain available for 90 days following the presentation. To access the webcast, please visit the Investors presentations tab of the Investors section of the Navidea website at www.navidea.com.

The LD Micro Invitational Conference is one of the nation’s largest independent conferences for small/micro-cap companies, with more than 230 names presenting to 1,000+ attendees. The conference will also feature a variety of speakers and panelists discussing topics of interest to investors and issuers, as well as evening social events.

The BIO International Convention (BIO) attracts 16,000+ biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. The Convention brings together a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.

To schedule a meeting with Navidea management at either conference, please contact Navidea Investor Relations at [email protected].

About BIO:

BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO’s blog chronicling "innovations transforming our world" and the BIO Newsletter is the organization’s bi-weekly email newsletter.

About LD Micro:

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. The firm hosts several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe. For those interested in attending, please contact David Scher at [email protected] or visit www.ldmicro.com for more information.

On May 30, 2018 AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, reported the appointment of Dr. James Pennington as the Company’s Chief Medical Officer (Press release, AzurRx BioPharma, MAY 30, 2018, View Source [SID1234526949]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted to welcome Jim to the senior management team as we rapidly advance our clinical programs," commented Thijs Spoor, CEO of AzurRx BioPharma. "Jim is a highly accomplished pharmaceutical industry executive with extensive medical and clinical experience, as well as hands-on experience in regulatory affairs. His appointment is timely as 2018 is shaping up to be a pivotal year for AzurRx, with a number of upcoming and potentially value enhancing milestones including the initiation of the MS1819 Phase 2 study in cystic fibrosis patients and the filing of the investigational drug application ("IND") in the U.S. for MS1819. We look forward to Jim’s leadership and contributions as these programs move forward."

"I am excited to join the AzurRx team at this exciting time for the Company," said Dr. Pennington. "We look forward to initiating a cystic fibrosis study later this year. MS1819, which has generated promising interim results in the ongoing study in chronic pancreatitis patients, addresses a billion-dollar market in exocrine pancreatic insufficiency. It has the potential to become best in class due to the high pill burden, patient compliance issues, and manufacturing/supply chain challenges of the current animal-derived therapies."

Dr. Pennington brings over 30 years of experience in the pharmaceutical industry. He served as Vice President at Bayer Corporation where, under his direct supervision, Bayer received ten product approvals from the U.S. Food & Drug Administration ("FDA") and ten product approvals from foreign regulatory authorities. Dr. Pennington also held senior positions at multiple therapeutics companies, including CMO roles at Anthera Pharmaceuticals and CoTherix Inc. and Senior VP of Research, Development and Clinical Affairs at Alpha Therapeutics Corp. Dr. Pennington has participated in many FDA pre-IND meetings and has also participated in several FDA Advisory Panel meetings. He has served on various editorial boards as well as professional societies, such as the American Association of the Advancement of Science. He is involved in academia and is currently Clinical Professor of Medicine at the University of California in San Francisco. Dr. Pennington holds a B.A. from the University of Oregon and an M.D. from the University of Oregon Medical School and is Board Certified in internal medicine and infectious diseases.

On May 30, 2018 In a few days’ time, the ASCO (Free ASCO Whitepaper) Annual Meeting will take place in Chicago, USA (1-5 June 2018) (Press release, EORTC, MAY 30, 2018, View Source [SID1234526948]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This year’s theme "Delivering discoveries: expanding the reach of precision medicine" focuses on making precision medicine a reality by driving progress and expanding its reach so that every patient can have the opportunity to benefit," Dr. Bruce Johnson, ASCO (Free ASCO Whitepaper) President.

EORTC reported it will present the results of several studies:

Oral presentations
Fifteen-year results of the randomised EORTC trial 22922/10925 investigating internal mammary and medial supraclavicular (IM-MS) lymph node irradiation in stage I-III breast cancer. (Abstract 504)
Oral Abstract Session: Breast Cancer – Local/Regional/Adjuvant

Time: Monday, June 4, 2018, 8:00 AM – 11:00 AM

Authors: Philip Poortmans, Sandra Collette, Henk Struikmans, Karin De Winter, Erik Van Limbergen, Carine Kirkove, Volker Budach, Karine Peignaux-Casasnovas, Ernest Vonk, Desiree van den Bongard, Sofia Rivera, Daniel Zips, Geertjan Van Tienhoven, Matthias Guckenberger, Roxolyana Abdah-Bortnyak, Alain Fourquet, Harry G. M. Bartelink

Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6. (Abstract 3500)
Oral abstract Session: Gastrointestinal Cancer

Time: Tuesday, June 5, 2018, 9:45 AM – 12:45 PM

Authors: Hans-Joachim Schmoll, Karin Haustermans, Timothy Jay Price, Bernard Nordlinger, Ralf Hofheinz, Jean-Francois Daisne, Jaak Janssens, Baruch Brenner, Peter Schmidt, Hans Reinel, Stephan Hollerbach, Karel Caca, Florian W.B. Fauth, Carla Hannig, John Raymond Zalcberg, Niall C. Tebbutt, Murielle E. Mauer, Sandrine Marreaud, Manfred P. Lutz, Eric Van Cutsem

Poster presentations
Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE. (Abstract 11540)
Poster Session: Sarcoma

Time: Saturday, June 2, 2018 – 8:00 – 11:30 AM

Authors: Patrick Schöffski, Agnieszka Wozniak, Bernd Kasper, Steinar Aamdal, Michael Gordon Leahy, Piotr Rutkowski, Sebastian Bauer, Hans Gelderblom, Antoine Italiano, Lars H Lindner, Ivo M. Hennig, Sandra J. Strauss, Branko Zakotnik, Alan Anthoney, Birgit Geoerger, Jean-Yves Blay, Peter Reichardt, Winette TA van der Graaf, Sandrine Marreaud, Silvia Stacchiotti

Doxorubicin plus dacarbazine (DoDa), doxorubicin plus ifosfamide (DI) or doxorubicin alone (Do) as first line treatment for advanced leiomyosarcoma (LMS): A retrospective study from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG). (Abstract 11574)
Poster Session: Sarcoma

Time: Saturday, June 2, 2018 – 8:00 – 11:30 AM

Authors: Lorenzo D’Ambrosio, Nathan Touati, Jean-Yves Blay, Giovanni Grignani, Ronan Flippot, Anna Malgorzata Czarnecka, Sophie Piperno-Neumann, Javier Martin Broto, Roberta Sanfilippo, Daniela Katz, Florence Duffaud, Bruno Vincenzi, Bernd Kasper, Daniel P. Stark, Filomena Mazzeo, Armin Tuchscherer, Saskia Litiere, Ward Sents, Hans Gelderblom, Alessandro Gronchi, on behalf of the EORTC STBSG

BEST OF: A phase III study assessing the best of radiotherapy (Intensity Modulated RadioTherapy, IMRT) compared to the best of surgery (Trans-Oral Surgery, TOS) in patients with T1-T2, N0 oropharyngeal squamous cell carcinoma (OPSCC). (Abstract TPS6098)
Poster Session: Head and Neck Cancer

Time: Saturday, June 2, 2018, 1:15 – 4:45 PM

Authors: Christian Simon, Carmela Aves Caballero, Catherine Fortpied, Mererid Evans, Petri Koivunen, Jean-Jacques Stelmes, Maria Urbanowicz, Jean Bourhis, Frank Zimmermann, Jens Peter Klussmann, Andreas Dietz, Giuseppe Spriano, C. Rene Leemans, Susanne Singer, Inge Tinhofer, Joanne Patterson, Silvana Quaglini, Keith Hunter, Vincent Gregoire

Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) inpatients with recurrent and/or metastatic androgen receptor (AR) expressing SGC (NCT01969578). (Abstract TPS6099)
Poster Session: Head and Neck Cancer

Time: Saturday, June 2, 2018, 1:15 – 4:45 PM

Authors: Laura Locati, Carmela Aves Caballero, Catherine Fortpied, Federica Perrone, Pasquale Quattrone, Kevin Harrington, Vincent Gregoire, Lisa F. Licitra

EORTC 1559-HNCG: A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)—"UPSTREAM". (Abstract TPS6095)
Poster Session: Head and Neck Cancer

Time: Saturday, June 2, 2018, 1:15 – 4:45 PM

Authors: Rachel Galot, Lisa F. Licitra, Christophe Le Tourneau, Joel Guigay, Inge Tinhofer, Anthony Hee Kong, Carmela Aves Caballero, Catherine Fortpied, Anne-Sophie Govaerts, Dominiek Staelens, Tiana Raveloarivahy, Jean-Francois Laes, Jean-Luc Re Canon, Stéphanie Henry, Esma Saada-Bouzid, Jean-Pascal H. Machiels

Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406). (Abstract 2023)
Poster Session: Central Nervous, System Tumors

Time: Saturday, June 2, 2018, 1:15 PM – 4:45 PM

Authors: Martin J. Van Den Bent, Pim French, Marica Eoli, Juan M. Sepúlveda, Anna Maria Elisabeth Walenkamp, Jean-Sebastien Frenel, Enrico Franceschi, Paul M. Clement, Michael Weller, Iris de Heer, Jim Looman, Jyotirmoy Dey, Scott Krause, Hao Xiong, Peter J Ansell, Sarah Nuyens, Maarten Spruyt, Joana Brilhante, Thierry Gorlia, Vassilis Golfinopoulos

A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209. (Abstract 6021)
Poster Discussion Session: Head and Neck Cancer

Time: Saturday, June 2, 2018, 4:45 – 6 PM

Authors: Martin Schlumberger, Kate Newbold, Baktiar Hasan, Sandrine Marreaud, Samson Assele, Lisa F. Licitra, Patrick Schoffski, Sophie Leboulleux, Laura Locati, Yann Godbert, Vincent Rohmer, Barbara Jarzab, Salvatore Domenico, Oliver Edgar Bechter, Sylvie Zanetta, Jaume Capdevila, Ellen Kapiteijn, Lars Bastholt

EORTC-ESSO 1409 GITCG: A prospective colorectal liver metastasis database with an integrated quality assurance program (CLIMB). (Abstract 3558)
Poster Session: Gastrointestinal Cancer

Time: Sunday, June 3, 2018, 8:00 – 11:30 AM

Authors: Carmela Aves Caballero, Lucia Carrion Alvarez, Henrik Nilsson, Theo Ruers, Perrine Senellart, Michel Rivoire, Stefan Stattner, Florian Primavesi, Roberto Troisi, Thomas Gruenberger, Jan Heil, Andreas Schnitzbauer, Nuh N. Rahbari, Rutger-Jan Swijnenburg, Hassan Zakria Malik, Mladjan Protic, Anouk Neven, Murielle E. Mauer, Graeme John Poston, Serge Evrard

On May 30, 2018 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, reported that the company will present at the Jefferies 2018 Global Healthcare Conference in New York (Press release, Corvus Pharmaceuticals, MAY 30, 2018, View Source;p=RssLanding&cat=news&id=2351343 [SID1234526947]). The presentation is scheduled for Wednesday, June 6, at 10:00 a.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available live and for 30 days following the event. The webcast may be accessed via the conference website and from the investor relations section of the Corvus website.